Mersana Therapeutics

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mersana Therapeutics excels in 2022, poised for oncology innovation

Mersana Therapeutics demonstrated strong performance, financial stability, and clinical progress in 2022, positioning themselves as a key player in oncology drug development.
While facing challenges in regulatory considerations and competitive dynamics, the company's strategic collaborations and pipeline advancements offer promising opportunities for future growth.
Investors should monitor Mersana's upcoming milestones, including data reporting and trial progress, as indicators of their potential for continued success and innovation.

Mersana Therapeutics progresses in Q1 with strong financials and clinical trials

Mersana Therapeutics is on track for a pivotal year with strong financials, progress in clinical trials, and plans for potential BLA submission. Challenges include diagnostic testing bottlenecks and patient pre-treatment impact on response rates. Opportunities exist in data presentations, partnerships, and subgroup analysis for improved outcomes.

Mersana Therapeutics reports improved Q3 performance and strategic partnerships

Mersana Therapeutics demonstrated improved financial performance, strong partnerships, and a focus on innovative ADC candidates. While facing challenges with clinical setbacks, the company's strategic restructuring and promising pipeline indicate opportunities for growth and success in the ADC market.

Mersana Therapeutics shows financial improvement and pipeline promise in Q1

Mersana Therapeutics demonstrated improved financial performance in Q1 2024 with reduced expenses and a lower net loss compared to the previous year.
Strengths in ADC platform advancements and promising lead candidates position Mersana well for future growth and innovation.
Challenges in clarifying key strategies and managing expenses underscore areas for improvement, while opportunities in expansion and partnerships offer avenues for advancement.

Mersana Therapeutics reports strong Q2 progress amidst financial challenges

Mersana Therapeutics demonstrated strong progress in Q2 2024 with promising clinical data for XMT-1660 and XMT-2056 ADC candidates, despite reporting a net loss.
The company's focus on optimizing dosing schedules, exploring biomarkers, and addressing resistance mechanisms underscores a commitment to advancing its pipeline.
Analysts' interest in patient responses, dosing schedules, and expansion plans highlights the market's anticipation of Mersana's future growth and innovation in the ADC space.

Mersana Therapeutics progresses ADC trials, strengthens finances, and faces resistance

Mersana Therapeutics demonstrated strong performance in advancing ADC candidates and managing finances effectively in Q3 2024.
While facing challenges such as resistance to existing ADCs, the company is well-positioned to capitalize on opportunities in innovative therapies.
Strategic planning for clinical trial expansions and business development will be crucial for Mersana's continued growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Phase 1 trial of XMT-2056 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). This action follows the company's communication to FDA that Mersana was voluntarily suspending the trial due to a recent Grade 5 (fatal) serious adverse event (SAE) that was deemed to be related to XMT-2056. The SAE and its cause remain under investigation.

Mersana Therapeutics Announces Clinical Hold on XMT-2056 Phase 1 Clinical Trial

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB.

Mersana Therapeutics Provides Statement About SVB

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q4 2022 Earnings Conference Call February 28, 2023 8:00 AM ET Company Participants Jason Fredette - SVP, IR and Corporate Communications Anna Protopapas - President and CEO Arvin Yang - Chief Medical Officer Brian DeSchuytner - CFO Conference Call Participants Jonathan Chang - SVB Securities Ashiq Mubarack - Citi Asthika Goonewardene - Truist Securities Boris Peaker - Cowen Operator Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2022 Conference Call and Webcast. Currently, all participants are in a listen-only mode.

Mersana Therapeutics, Inc. (MRSN) Q4 2022 Earnings Call Transcript

CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

CAMBRIDGE, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2022 on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Mersana Therapeutics to Host Fourth Quarter and Year End 2022 Conference Call on February 28, 2023

First Immunosynthen ADC product candidate enters the clinic First Immunosynthen ADC product candidate enters the clinic

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors

Mersana has excellent ADC science. A number of big pharma have bought into the science.

Mersana: I Like The Science, Derisking Will Come From More Proof

CAMBRIDGE, Mass., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and announced strategic objectives and expected milestones for 2023.

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen ADCs directed against up to two targets. Immunosynthen, Mersana's proprietary STING-agonist ADC platform, is designed to generate systemically administered ADCs that locally activate STING signaling in both ​tumor-resident immune cells and in antigen-expressing tumor cells, unlocking the anti-tumor potential of innate immune stimulation.​

Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

CAMBRIDGE, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the European Commission (EC) has designated upifitamab rilsodotin (UpRi) as an orphan medicinal product for the treatment of ovarian cancer. UpRi is Mersana's first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that is designed to enable a high drug-to-antibody ratio and controlled bystander effect.

European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President and Chief Executive Officer Arvin Yang - Senior Vice President and Chief Medical Officer Brian DeSchuytner - Senior Vice President and Chief Financial Office Conference Call Participants Jonathan Chang - SVB Securities Colleen Kusy - Baird Kaveri Pohlman - BTIG David Nierengarten - Wedbush Boris Peaker - Cowen & Co Operator Good morning, and welcome to Mersana Therapeutics Third Quarter 2022 Conference Call and webcast. Currently, all participants are in a listen-only mode.

Mersana Therapeutics, Inc. (MRSN) Q3 2022 Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2022.

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the third quarter ended September 30, 2022 on Monday, November 7, 2022 and will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022

CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the completion of patient enrollment in UPLIFT, the company's single-arm registrational trial of UpRi in platinum-resistant ovarian cancer. UpRi is Mersana's first-in-class NaPi2b-targeting ADC with a novel scaffold-linker-payload that enables a high drug-to-antibody ratio and controlled bystander effect.

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company, today announced the launch of Oncology FACETS: an educational platform for healthcare providers that will address clinically impactful topics in gynecologic oncology. Oncology FACETS is driven by a Steering Committee of experts in gynecologic oncology and offers content developed in collaboration with Mersana.

Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Mersana Therapeutics, Inc. (MRSN) Just Flashed Golden Cross Signal: Do You Buy?

Shares of Mersana Therapeutics are up 21% in 2022 and +168% over the past 3 years. Management sees lead antibody drug conjugate UpRi gaining broad use in ovarian cancer, though I remain skeptical.

Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed

Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang - Senior VP & Chief Medical Officer Brian DeSchuytner - Senior VP & CFO Conference Call Participants Jonathan Chang - SVB Securities Colleen Kusy - Baird Operator Good afternoon, and welcome to Mersana Therapeutics Second Quarter 2022 Conference Call and webcast. Currently, all participants are in a listen-only mode.

Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2022 Results - Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the second quarter ended June 30, 2022.

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced a global collaboration that provides GSK plc (LSE/NYSE: GSK) an exclusive option to co-develop and commercialize XMT-2056, an Immunosynthen ADC that targets a novel epitope of HER2. XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells.

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the second quarter ended June 30, 2022 on Monday, August 8, 2022 and will host a conference call and webcast at 4:30 p.m. Eastern Time that afternoon. Members of management will also be presenting at two upcoming conferences. Details are as follows:

Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

CAMBRIDGE, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that its Senior Vice President and Chief People Officer, Carla Poulson, has been named one of Savoy Magazine's 2022 Most Influential Black Executives in Corporate America.

Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine's 2022 Most Influential Black Executives in Corporate America

The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for Mersana Therapeutics Stock (MRSN)